Arabic Arabic English English French French German German
dark

NeoImmuneTech to Present at Society for Neuro-Oncology Annual Meeting

NeoImmuneTech, Inc. today announced that new data from a Phase 1/2 study evaluating the company’s lead asset NT-I7 (efineptakin alfa) will be presented during oral abstract sessions at the Society for Neuro-Oncology (SNO) annual meeting, to be held in Boston, Massachusetts on November 18-21, 2021. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Industry Veteran Rusty Williams Leads Startup to $50 Million Series A

Next Post

Successful demonstration of BioDrone® platform-based drug delivery and confirmed restoration of the myogenic potential of Prokr1-deficient C2C12 myoblasts

Related Posts
Total
0
Share